MorphoSys宣布美国根据HSR法案批准诺华公司的拟议收购-动脉网

MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act

BioSpace 等信源发布 2024-03-22 15:19



可切换为仅中文







PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 22, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced the receipt of U.S. antitrust clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the 'HSR Act') in connection with the proposed acquisition of MorphoSys by Novartis AG ('Novartis'), following the expiration of the HSR Act waiting period.

PLANEGG and MUNICH，GERMANY/ACCESSWIRE/2024年3月22日/MorphoSys AG（FSE:MOR）（NASDAQ:MOR）今天宣布，根据1976年《哈特-斯科特-罗迪诺反托拉斯改进法案》（“HSR法案”），收到美国反托拉斯许可证，涉及诺华公司（“诺华”）在HSR法案等待期到期后拟收购MorphoSys。

MorphoSys previously also announced the receipt of antitrust clearance in Germany and Austria. As a result, the proposed acquisition of MorphoSys by Novartis has now received all mandatory regulatory approvals..

MorphoSys此前还宣布已获得德国和奥地利的反垄断许可。因此，诺华对MorphoSys的拟议收购现已获得所有强制性监管批准。。

On February 5, 2024, MorphoSys announced the intention of Novartis to submit a voluntary public takeover offer for all outstanding MorphoSys no-par value bearer shares at an offer price of € 68.00 per share in cash (the 'Takeover Offer'), representing a total equity value of € 2.7 billion. The offer document of the Takeover Offer is expected to be published by Novartis in April 2024 in accordance with the provisions of the German Securities Acquisition and Takeover Act, after the German Federal Financial Supervisory Authority ('BaFin') has approved the publication.

2024年2月5日，MorphoSys宣布，诺华有意以每股68.00欧元的现金要约价格（“收购要约”）为所有已发行的MorphoSys无面值无记名股票提交自愿公开收购要约，总股本为27亿欧元。在德国联邦金融监管局（“BaFin”）批准发布收购要约后，诺华预计将于2024年4月根据《德国证券收购和收购法》的规定发布收购要约的要约文件。

Once the offer document is published by Novartis, the acceptance period for MorphoSys shareholders to tender their shares will begin. The Takeover Offer will require a minimum acceptance threshold of 65% of MorphoSys' share capital, among other customary closing conditions..

一旦诺华发布要约文件，MorphoSys股东将开始接受其股票的投标。收购要约将要求最低接受门槛为MorphoSys股本的65%，以及其他惯常的交割条件。。

MorphoSys and Novartis continue to expect the closing of the Takeover Offer to take place in the first half of 2024.

MorphoSys和诺华继续预计收购要约将在2024年上半年结束。

About MorphoSys

关于MorphoSys

At MorphoSys, we are driven by our mission: More life for people with cancer. As a global commercial-stage biopharmaceutical company, we develop and deliver innovative medicines, aspiring to redefine how cancer is treated. MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts.

在MorphoSys，我们的使命是：为癌症患者提供更多的生命。作为一家全球商业化的生物制药公司，我们开发并提供创新药物，致力于重新定义癌症的治疗方式。MorphoSys总部位于德国Planegg，其美国业务位于马萨诸塞州波士顿。

To learn more, visit us at www.morphosys.com and follow us on Twitter at X and LinkedIn..

要了解更多信息，请访问我们的网站www.morphosys.com，并在推特X和LinkedIn上关注我们。。

Additional Information and Where to Find it

其他信息以及在哪里可以找到

The takeover offer described in this communication (the 'Takeover Offer') has not yet commenced. This communication is neither an offer to purchase nor a solicitation of an offer to sell shares of MorphoSys AG (the 'Company'). The final terms and further provisions regarding the Takeover Offer will be in the offer document once the publication of the offer document by Novartis BidCo AG (formerly known as Novartis data42 AG) (the 'Bidder') has been approved by the German Federal Financial Supervisory Authority (the 'BaFin'), after which the offer document will be filed with the U.S.

本函件中描述的收购要约（“收购要约”）尚未开始。本通信既不是购买MorphoSys AG（“公司”）股份的要约，也不是出售MorphoSys AG（“公司”）股份的要约。一旦诺华BidCo AG（以前称为诺华data42 AG）（“投标人”）发布的要约文件获得德国联邦金融监管局（“BaFin”）的批准，有关收购要约的最终条款和进一步规定将在要约文件中，然后将要约文件提交给美国。

Securities and Exchange Commission (the 'SEC'). A solicitation and an offer to buy shares of the Company will be made only pursuant the offer document. In connection with the Takeover Offer, the Bidder and Novartis AG will file a Tender Offer Statement on Schedule TO with the SEC (together with the offer document, an Offer to Purchase including the means to tender and other related documents, the 'Takeover Offer Documents'), the Company's management board and supervisory board will issue a joint reasoned statement in accordance with sec.

美国证券交易委员会（“SEC”）。仅根据要约文件进行招标和要约购买公司股份。关于收购要约，投标人和诺华公司将按计划向SEC提交一份收购要约声明（连同要约文件、收购要约，包括投标方式和其他相关文件，简称“收购要约文件”），公司管理委员会和监事会将根据SEC发布一份联合合理声明。

27 of the German Securities Acquisition and Takeover Act and the Company will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC (together with the joint reasoned statement, the 'Recommendation Statements'). THE COMPANY'S STOCKHOLDERS AND OTHER INVESTORS ARE URGED TO READ THE TAKEOVER OFFER DOCUMENTS AND THE RECOMMENDATION STATEMENTS BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION WHICH SHOULD BE READ CAREFULLY BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TAKEOVER OFFER.

根据《德国证券收购与收购法》第27条的规定，公司将按照附表14D-9向SEC提交一份征集/推荐声明（连同联合合理声明，简称“推荐声明”）。敦促公司股东和其他投资者阅读收购要约文件和推荐声明，因为它们将包含重要信息，在就收购要约做出任何决定之前，应仔细阅读这些信息。

The Takeover Offer Documents and the Recommendation Statements will be distributed to all stockholders of the Company in accordance with German and U.S. securities.

收购要约文件和推荐声明将按照德国和美国证券的规定分发给公司的所有股东。

In addition to the Offer to Purchase, including the means to tender and certain other Takeover Offer Documents, as well as the Solicitation/Recommendation Statement, the Company files other information with the SEC. The Company's filings with the SEC are also available for free to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov and are also available free of charge under the 'SEC Filings' section of the Company's website at www.morphosys.com/en/investors..

除了收购要约，包括投标方式和某些其他收购要约文件，以及招标/推荐声明外，公司还向美国证券交易委员会提交了其他信息。公司向美国证券交易委员会提交的文件也可以通过商业文件检索服务和美国证券交易委员会维护的网站www.SEC.gov免费获得，也可以在公司网站www.morphosys.com/en/investors的“SEC文件”部分免费获得。。

In order to reconcile certain areas where German law and U.S. law conflict, Novartis AG and the Bidder expect to request no-action and exemptive relief from the SEC to conduct the Takeover Offer in the manner described in the offer document.

为了调和德国法律和美国法律冲突的某些领域，诺华公司和投标人希望不要求SEC采取行动和豁免救济，以要约文件中描述的方式进行收购要约。

Acceptance of the Takeover Offer by stockholders residing outside Germany and the United States of America may be subject to further legal requirements. With respect to the acceptance of the Takeover Offer outside Germany and the United States, no responsibility is assumed for the compliance with such legal requirements applicable in the respective jurisdiction..

居住在德国和美国境外的股东接受收购要约可能需要进一步的法律要求。关于在德国和美国境外接受收购要约，不承担遵守适用于各自司法管辖区的此类法律要求的责任。。

Forward Looking Statements

前瞻性声明

This communication contains certain forward-looking statements concerning the Company, the Bidder and the Takeover Offer that involve substantial risks and uncertainties. Forward-looking statements include any statements containing the words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'intend,' 'goal,' 'may,' 'might,' 'plan,' 'predict,' 'project,' 'seek,' 'target,' 'potential,' 'will,' 'would,' 'could,' 'should,' 'continue' and similar expressions.

该通信包含有关公司、投标人和收购要约的某些前瞻性陈述，涉及重大风险和不确定性。前瞻性陈述包括任何包含“预期”、“相信”、“估计”、“期望”、“打算”、“目标”、“可能”、“可能”、“计划”、“预测”、“项目”、“寻求”、“目标”、“潜力”、“意志”、“将会”、“可能”、“应该”、“继续”等词语的陈述以及类似的表达。

In this communication, the Company's forward-looking statements include statements about the parties' ability to satisfy the conditions to the consummation of the Takeover Offer; statements about the expected timetable for the consummation of the Takeover Offer; the Company's plans, objectives, expectations and intentions; and the financial condition, results of operations and business of the Company and Novartis AG..

在本通讯中，公司的前瞻性声明包括关于各方满足完成收购要约条件的能力的声明；关于完成收购要约的预期时间表的声明；公司的计划、目标、期望和意图；以及公司和诺华公司的财务状况、经营成果和业务。。

The forward-looking statements contained in this communication represent the judgment of the Company as of the date of this communication and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of the Company, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements.

本通讯中包含的前瞻性陈述代表公司截至本通讯日期的判断，涉及已知和未知的风险和不确定性，可能导致公司的实际业绩、财务状况和流动性、业绩或成就或行业业绩与此类前瞻性陈述中明示或暗示的任何历史或未来业绩、财务状况和流动性、业绩或成就存在重大差异。

In addition, even if the Company's results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Those risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include, among other things: uncertainties as to the timing of the Takeover Offer; uncertainties as to how many of the Company's stockholders will tender their stock in the Takeover Offer; the possibility that competing offers will be made; the possibility that various conditions for the Takeover Offer may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the Takeover Offer; the effects of the Takeover Offer on relationships with employees, other business partners or governmental entities; that the Bidder and Novartis AG may not realize the potential benefits of the Takeover Offer; transaction costs associated with the Takeover Offer; that the Company's expectations may be incorrect; the inherent uncertainties associated with competitive developments, clinical trial and prod.

此外，即使公司的业绩、业绩、财务状况和流动性以及经营所在行业的发展与此类前瞻性报表一致，也可能无法预测未来时期的业绩或发展。可能导致实际结果与前瞻性声明预期不同的风险和不确定性包括：收购要约时间的不确定性；不确定公司有多少股东将在收购要约中出价；提出竞争报价的可能性；不满足或放弃收购要约的各种条件的可能性，包括政府实体可能禁止、延迟或拒绝批准完成收购要约；收购要约对员工、其他商业伙伴或政府实体关系的影响；投标人和诺华公司可能无法实现收购要约的潜在利益；与收购要约相关的交易成本；公司的期望可能不正确；与竞争发展，临床试验和产品相关的固有不确定性。

For more information, please contact:

有关更多信息，请联系：

Media Contacts:

媒体联系人：

Thomas Biegi

托马斯·比吉

Senior Vice President, Corporate Affairs

公司事务高级副总裁

Tel.: +49 (0)89 / 899 27 26079

电话：+49（0）89/899 27 26079

thomas.biegi@morphosys.com

Investor Contacts: